Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024 : vimarsana.com

PDUFA Target Action Date of June 26, 2024 Eight posters including two oral presentations support potential of ensifentrine,an investigational, first-in-class, selective, dual inhibitor of PDE3 and...

Related Keywords

United States , Texas , London , City Of , United Kingdom , Manchester , Alabama , Claremont , Surrey , American , Frank Sciurba , Mark Dransfield , Donald Mahler , Antonio Anzueto , Ravi Kalhan , Verona Pharma , Nathan Marchetti , Dave Singh , Leslie Humbel , Northwestern University , University Of Pittsburgh Medical Center , Lewis Katz School Of Medicine , American Thoracic Society International Conference , Temple University , Nasdaq , Bridge Communications , University Of Pittsburgh School Medicine , Globenewswire Inc , International Us Media Enquiries , University Of Manchester , Drug Administration , Action Date , Thoracic Society International Conference , Late Breaking Mini Symposium , Critical Care , Associate Professor , Pittsburgh School , Breaking Mini Symposium , Ensifentrine Reduces Exacerbation Frequency , Delays Progression , Pittsburgh Medical , Late Breaking Abstracts , Improved Lung Function , Reduced Exacerbations , Symptomatic Subjects , Alabama Birmingham , Selective Inhibitor , Severe Exacerbation Rate , Subjects With , Baseline Blood , Ensifentrine Added , Symptomatic Subjects With Moderate To Severe , Thoracic Medicine , Katz School , Life Reported With Ensifentrine , Pooled Analysis , Respiratory Pharmacology , Subjects With Symptomatic Moderate To Severe , Improved Dyspnea , Subjects With Symptomatic , Regional Hospital , Reduced Dyspnea , Improved Quality , Pulmonary Critical Care , Kingdom Tel , Senior Director , Investor Relations , Annual Report , Quarterly Reports ,